FDA supplemental approval: Fentanyl (REMS)

AI Summary

The FDA granted supplemental approval on 18 June 2026 for a REMS (Risk Evaluation and Mitigation Strategy) covering four strengths of fentanyl transdermal extended-release film products marketed by Mylan Technologies. This record documents a regulatory action but does not contain clinical trial results, efficacy data, or safety comparisons.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for fentanyl transdermal film products; this is a regulatory action, not a clinical trial, and does not report efficacy or safety trial outcomes.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action establishes required risk mitigation measures for fentanyl transdermal film products. Clinicians should consult the approved REMS documentation for prescribing requirements, patient counselling obligations, and dispensing controls, but this record does not provide clinical efficacy or comparative safety data to inform treatment decisions.

Caveats

• This regulatory record does not contain clinical trial results, efficacy endpoints, safety data, or comparator information.
• The specific content and requirements of the approved REMS programme are not detailed in this record.
• No information on why the REMS supplement was submitted or what changes it made to prior REMS terms.
• Approval of a REMS does not indicate new efficacy or safety findings; it documents regulatory compliance and risk management requirements.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.